(Q36835799)

16 August 2017

1 reference

title

In vitro approaches to investigate mechanism-based inactivation of CYP enzymes (English)

1 reference

16 August 2017

Thomas M Polasek

1

1 reference

16 August 2017

John O Miners

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

Expert Opinion on Drug Metabolism & Toxicology

16 August 2017

published in

1 reference

16 August 2017

volume

3

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

321-329

1 reference

Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Drug-mediated inactivation of cytochrome P450.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Mechanism-based inactivators as probes of cytochrome P450 structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Evolution of drug metabolism: hitchhiking the technology bandwagon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--toward a consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Utility of microtiter plate assays for human cytochrome P450 inhibition studies in drug discovery: application of simple method for detecting quasi-irreversible and irreversible inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Rapidly distinguishing reversible and irreversible CYP450 inhibitors by using fluorometric kinetic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Diclofenac-induced inactivation of CYP3A4 and its stimulation by quinidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

CYP3A4 drug interactions: correlation of 10 in vitro probe substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Cooperativity in oxidations catalyzed by cytochrome P450 3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Structural diversity of human xenobiotic-metabolizing cytochrome P450 monooxygenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Crystal structure of human cytochrome P450 2C9 with bound warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Mechanism-based inactivation and reversibility: is there a new trend in the inactivation of cytochrome p450 enzymes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Mechanism-based inactivation of CYP3A by HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Optimizing bacterial expression of catalytically active human cytochromes P450: comparison of CYP2C8 and CYP2C9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Biochemical and genetic factors influencing drug metabolism. Influence of hepatic microsomal mixed function oxidation reactions on cellular metabolic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Organization of multiple cytochrome P450s with NADPH-cytochrome P450 reductase in membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Mechanism-based inactivation of human cytochrome P450 1A2 by furafylline: detection of a 1:1 adduct to protein and evidence for the formation of a novel imidazomethide intermediate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.321

21 January 2018

Identifiers

DOI

10.1517/17425255.3.3.321

1 reference

16 August 2017

1 reference